Calcium Carbonate Microparticles as Carriers of 224 Ra: Impact of Specific Activity in Mice with Intraperitoneal Ovarian Cancer
Authors:
Open Access
- 4 June 2021
- journal article
- research article
- Published by Bentham Science Publishers Ltd. in Current Radiopharmaceuticals
- Vol. 14 (2) , 145-153
Abstract
Background: Patients with advanced-stage ovarian cancer face a poor prognosis because of recurrent peritoneal cavity metastases following surgery and chemotherapy. Alpha-emitters may enable the efficient treatment of such disseminated diseases because of their short range and highly energetic radiation. Radium-224 is a candidate α-emitter due to its convenient 3.6-day half-life, with more than 90% of the decay energy originating from α-particles. However, its inherent skeletal accumulation must be overcome to facilitate intraperitoneal delivery of the radiation dose. Therefore, 224Ra-labeled CaCO3microparticles have been developed. Objective: The antitumor effect of CaCO3microparticles as a carrier for 224Ra was investigated, with an emphasis on the ratio of activity to mass dose of CaCO3, that is, specific activity. Methods: Nude athymic mice were inoculated intraperitoneally with human ovarian cancer cells (ES-2) and treated with a single intraperitoneal injection of 224Ra-labeled CaCO3microparticles with varying combinations of mass and activity dose, or cationic 224Ra in solution. Survival and ascites volume at sacrifice were evaluated. Results: Significant therapeutic effect was achieved for all tested specific activities ranging from 0.4 to 4.6 kBq/mg. Although treatment with a mean activity dose of 1305 kBq/kg of cationic 224Ra prolonged the survival compared with the control, equivalent median survival could be achieved with 224Ra-labeled microparticles with a mean dose of only 420 kBq/kg. The best outcome was achieved with the highest specific activities (2.6 and 4.6 kBq/mg). Conclusion: Radium-224-labeled CaCO3microparticles present a promising therapy against cancer dissemination in body cavities.Keywords
Funding Information
- Norwegian Research Council (291228, 259820, 282220)
This publication has 37 references indexed in Scilit:
- Treatment for Recurrent Ovarian Cancer—At First RelapseJournal of Oncology, 2009
- Growth retardation and destruction of experimental squamous cell carcinoma by interstitial radioactive wires releasing diffusing alpha‐emitting atomsInternational Journal of Cancer, 2008
- Treatment of solid tumors by interstitial release of recoiling short-lived alpha emittersPhysics in Medicine & Biology, 2007
- Phase III Trial of Intraperitoneal Therapy With Yttrium-90–Labeled HMFG1 Murine Monoclonal Antibody in Patients With Epithelial Ovarian Cancer After a Surgically Defined Complete RemissionJournal of Clinical Oncology, 2006
- Sterically stabilized liposomes as a carrier for α-emitting radium and actinium radionuclidesNuclear Medicine and Biology, 2004
- α-Particle Radiotherapy with 211At-Labeled Monodisperse Polymer Particles, 211At-Labeled IgG Proteins, and Free 211At in a Murine Intraperitoneal Tumor ModelGynecologic Oncology, 1995
- Therapeutic efficacy of the α-emitter 211At bound on microspheres compared with 90Y and 32P colloids in a murine intraperitoneal tumor modelGynecologic Oncology, 1992
- Randomized trial comparing cisplatin with radioactive phosphorus or whole-abdomen irradiation as adjuvant treatment of Ovarian cancerCancer, 1992
- Complications from intraperitoneal radioactive phosphorus in ovarian malignanciesGynecologic Oncology, 1985
- Radiocolloids in the Treatment of Ovarian CancerObstetrical & Gynecological Survey, 1979